Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse Exon20ins were used to characterize the antitumor mechanism of amivantamab. Amivantamab inhibited proliferation by effectively downmodulating EGFR–MET levels and inducing immune-directed antitumor activity with increased IFNγ secretion in various models. Importantly, in vivo efficacy of amivantamab was superior to cetuximab or poziotinib, an experimental Exon20ins-targeted TKI. Amivantamab produced robust tumor responses in two Exon20ins patients, highlighting the important translational nature of this preclinical work. These findings provide mechanistic insight into the activity of amivantamab and support its continued clinical development in Exon20ins patients, an area of high unmet medical need. Significance: Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC. Preclinical data shown here, together with promising clinical activity in an ongoing phase I study, strongly support further clinical investigation of amivantamab in EGFR Exon20ins–driven NSCLC. This article is highlighted in the In This Issue feature, p. 1079
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results were replicated in clinical trials (for example, NCT04538664), eventually leading to the approval of amivantamab by the EMA for the treatment of non-small cell lung cancer.”
From Human disease models in drug development (2023) · cites this paper as [115]
In the citing paper
“the efficacy of amivantamab, a bispecific antibody against EGFR and the mesenchymal–epithelial transition receptor, was preclinically tested in patient-derived cells and organoids that harbour EGFR Exon20ins mutations115.”
From Human disease models in drug development (2023) · cites this paper as [115]
Citations
Cites
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“Nearly 20% of Caucasians and up to 50% of Asians with lung adenocarcinomas harbor mutations in EGFR (3,4).”
BackgroundLong‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082 · cited 1×
“PDO Culture PDOs (YUO-029 and YUO-036) were established as described previously (46).”
MethodGazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · cited 1×
“tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and osimertinib (5,6).”
BackgroundRegulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891 · cited 1×
“It is known that inflammatory cytokines such as IFN-γ and TNFα are secreted from infected monocytes and activated NK cells during ADCC, encouraging antigen presentation and adaptive immune responses (36,37).”
BackgroundMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775 · cited 1×
“Given that mutant TP53 is associated with EGFR-TKI resistance (30) and the depleted mutant TP53 restored the sensitivity of amivantamab by downregulation of p-ERK, induction of p-ERK following amivantamab treatment in YU-1163 cells might be a key regulator of cell survival potentially through the crosstalk between mut…”
BackgroundYasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · cited 1×
“In contrast, the EGFR exon 20 mutations encompass nucleotides that translate into amino acids at position 762-823, and include a C-helix (762–766) followed by a loop (767–775) (7).”
BackgroundNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567 · cited 1×
“The effector cells, mainly natural killer (NK) cells, trigger degranulation and subsequent cytokine production, resulting in the elimination of the target cells (33).”
BackgroundIntra-tumour diversification in colorectal cancer at the single-cell level
Roerink, S. F., Sasaki, N., Lee-Six, H., Young, M. D., Alexandrov, L. B., Behjati, S., Mitchell, T. J., Grossmann, S., Lightfoot, H., Egan, D. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0024-3 · Cited by 551
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499 · cited 1×
“As EGFR-TKIs have been reported to drive apoptosis in NSCSL cells harboring sensitizing EGFR mutations (24,25), we investigated whether treatment with amivantamab resulted in engagement of the apoptotic machinery.”
Background
Cited by
Items 101–200 of 301
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
Spitaleri, G., Aliaga, P. T., Attili, I., Signore, E. D., Corvaja, C., Corti, C., Uliano, J., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15194779 · Cited by 29
Fan, Y., Duan, Y., Chen, J., Wang, Y., Shang, K., Jiang, J., Su, L., Zhou, C., Sadelain, M., Huang, H., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01450-4 · Cited by 24
Koopman, B., Garcia, B. N. C., Kuijpers, C. C. H. J., Damhuis, R. A. M., van der Wekken, A. J., Groen, H. J. M., Schuuring, E. M. D., Willems, S. M., & van Kempen, L. C. L. T. (2021) · Cancers · doi:10.3390/cancers13143641 · Cited by 24
“However, these perspectives might change with new evidence: for example, there are promising novel agents and combination therapies currently under investigation that may be effective against EGFR exon 20 insertions, including amivantamab [79], poziotinib [80], and mobocertinib [81], or combining osimertinib or afatin…”
BackgroundBrazel, D., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s337861 · Cited by 26
“Preclinical studies on Ba/F3 cell lines containing EGFR exon 20 mutations showed amivantamab decreased EGF and cMet receptor expression.(23) This study examined five different exon 20 insertions: (V769_D770insASV, D770delinsGY, H773_V774insH, Y764_V765insHH, and D770_N771ins-SVD).”
BackgroundInfluentialEGFR-mutant NSCLC: emerging novel drugs
Ye, L., Chen, X., & Zhou, F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000701 · Cited by 24
“Amivantamab is a fully human bispecific antibody targeting EGFR and MET and has demonstrated clinical activity in patients with diverse EGFR mutations [49], including EGFR20ins [50].”
BackgroundHuang, C., Ju, J., Chiu, T.-H., Huang, A. C., Tung, P., Wang, C., Liu, C., Chung, F., Fang, Y., Guo, Y., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33821 · Cited by 22
“Recently, some promising results involving other irreversible EGFR-TKI or monovalent bispecific monoclonal antibody also shed light on new treatment options for patients of EGFR exon 20 insertion mutation.(40,41) In our study, patients of the type-II uncommon EGFR mutation exhibited a bipolar tumour behaviour, with ei…”
BackgroundWei, M., Zuo, S., Chen, Z., Qian, P., Zhang, Y., Kong, L., Gao, H., Wei, J., & Dong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017574 · Cited by 26
Sa, H., Shi, Y., Ding, C., & Ma, K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04726-x · Cited by 28
Zhang, J., Yang, T., Han, M., Wang, X., Yang, W., Guo, N., Ren, Y., Cui, W., Li, S., Zhao, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc9273 · Cited by 27
Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
Thomas, B. J., Guldenpfennig, C., Guan, Y., Winkler, C., Beecher, M., Beedy, M., Berendzen, A. F., Ma, L., Daniëls, M. A., Burke, D. H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102046 · Cited by 26
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
Kim, S., Park, J. M., Park, S., Jung, E., Ko, D., Park, M., Seo, J., Nam, K. D., Kang, Y. K., Lee, K., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02866-z · Cited by 25
“S3) in agreement with previous observations in NSCLC [21].”
ResultSelf-citationMountzios, G., Planchard, D., Metro, G., Tsiouda, D., Prelaj, A., Lampaki, S., Shalata, W., Riudavets, M., Christopoulos, P., Girard, N., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100433 · Cited by 20
Chang, J. W., Huang, C., Fang, Y., Chang, C., Yang, C., Kuo, C. S., Hsu, P., & Wu, C. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14537 · Cited by 23
Aronchik, I., Kar, S., Zhuang, Y., Ahler, E., Lai, L., Seshadri, V., Yang, Y. C., Bulle, A. S., Ménard, M., Nayak, B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04537-w · Cited by 32
“Given the detection of c-MET alterations in the ctDNA of some patients who progressed on daraxonrasib monotherapy and the reciprocal relationship of c-MET and EGFR in the context of KRAS G12C(OFF) inhibitor resistance in PDAC 35 , we hypothesized that the combined inhibition of c-MET and EGFR may effectively block acq…”
InfluentialTargeted therapies in non-small cell lung cancer: present and future
McLaughlin, J., Berkman, J. D., & Nana-Sinkam, P. S. (2023) · Faculty Reviews · doi:10.12703/r/12-22 · Cited by 24
Yao, H., Hudson, R., & Wang, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188425 · Cited by 20
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Kim, J., Park, S., Ku, B. M., & Ahn, M. (2025) · Cancer · doi:10.1002/cncr.35778 · Cited by 29
Self-citationKumaki, Y., Olsen, S., Suenaga, M., Nakagawa, T., Uetake, H., & Ikeda, S. (2021) · Current Oncology · doi:10.3390/curroncol28050317 · Cited by 22
“Additionally, amivantamab is an EGFR–MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR mutations and MET mutations and amplifications [14].”
Backgroundc-Met Signaling as a Therapeutic Target in Head and Neck Cancer
Centuori, S. M., & Bauman, J. E. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000619 · Cited by 19
“In addition to tumor-intrinsic antisignaling activity, amivantamab has shown immune-directing antitumor activity including antibody-dependent cellular cytotoxicity in NSCLC models.(87)”
BackgroundThe development of amivantamab for the treatment of non-small cell lung cancer
Brazel, D., & Nagasaka, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02558-4 · Cited by 24
Krebs, M., Cho, B. C., Hiret, S., Han, J., Lee, K. H., Pérez, C. L., de Braud, F., Haura, E. B., Sanborn, R. E., Yang, J. C., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.012 · Cited by 18
Self-citationNagasaka, M., Balmanoukian, A. S., Madison, R. W., Zhang, S. S., Klempner, S. J., & Ou, S. I. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.022 · Cited by 18
Advance in identified targets of berberine
Sun, P., Wang, Z., Ma, Y., Liu, Y., Xue, Y., Li, Y., Gao, X., Wang, Y., & Chu, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1500511 · Cited by 19
Application of EGFR-TKIs in brain tumors, a breakthrough in future?
Feng, S., Liu, H., Yun, C., Zhu, W. Z., & Pan, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06448-9 · Cited by 20
“EGFR mutations occur in approximately 30–40% of non-small cell lung cancer (NSCLC) patients [98, 99].”
Khan, S., Upadhyay, S., Kauser, S., Hasan, G. M., Lu, W., Waters, M., Hassan, M. I., & Sohal, S. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228021 · Cited by 20
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision
Lai, G. G. Y., Guo, R., Drilon, A. E. D. C., & Tan, D. S. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102444 · Cited by 18
Duan, J., Wu, L., Yang, K., Zhao, J., Zhao, Y., Dai, X., Li, M., Xie, Y., Yao, Y., Zhao, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1449 · Cited by 22
Hu, M., Zhong, C., Wang, J., Chen, J., & Zhou, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399975 · Cited by 19
Zawily, A. E., Vizeacoumar, F. S., Dahiya, R., Banerjee, S. L., Bhanumathy, K. K., Elhasasna, H., Hanover, G., Sharpe, J. C., Sanchez, M. G., Greidanus, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2535 · Cited by 17
“BMX-661 proved to be effective in xenograft cancer models at a relatively low dose of 2 mg/kg/wk compared with doses exceeding 15 mg/kg/wk often used for testing RTK-targeting antibodies for therapeutic ef fi ciency (47 – 49).”
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC
Passiglia, F., Malapelle, U., Normanno, N., & Pinto, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102438 · Cited by 16
Advances in the clinical application of bispecific antibodies in cancer therapy
Zhou, S., Feng, L., Niu, M., Wu, K., Li, T., & Yi, M. (2025) · iScience · doi:10.1016/j.isci.2025.114203 · Cited by 20
“59 Other designs, such as HER2 × HER3 BsAbs, inhibit receptor dimerization and down-stream signaling.”
Zhu, X., Liang, C., Chen, J., Gao, J., Chen, W., Ouyang, Q., Luo, L., Huang, Z., Luo, L., Chen, L., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.148136 · Cited by 16
Antonarelli, G., Pieri, V., Porta, F. M., Fusco, N., Finocchiaro, G., Curigliano, G., & Criscitiello, C. (2023) · Cells · doi:10.3390/cells12060840 · Cited by 17
“As a matter of fact, afucosylated Fc glycans exhibit a high affinity for FcgRIIIa glycans, increasing antibody-dependent cell cytotoxicity (ADCC) [88,89], and this property is already being exploited in drug engineering, as with Amivantamab, a bispecific antibody [90,91].”
BackgroundDiverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy
Seervai, R. N. H., Cho, W. C., Chu, E. Y., Marques-Piubelli, M. L., Ledesma, D. A., Richards, K. N., Heberton, M. M., Nelson, K. C., Nagarajan, P., Torres-Cabala, C. A., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14145 · Cited by 15
Organoids in Lung Cancer Management
Li, Y., Chan, J. W. Y., Lau, R. W. H., Cheung, W. W. Y., Wong, A. M., Wong, A. M., Wong, N., & Ng, C. S. H. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.753801 · Cited by 14
Sarhan, M. O., Haffez, H., Elsayed, N. A., El-Haggar, R. S., & Zaghary, W. A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106924 · Cited by 15
Liu, A., Wang, X., Wang, L., Han, Z., Xiong, L., Gan, X., Wang, Q., & Tao, G. (2024) · BMC Cancer · doi:10.1186/s12885-024-13168-8 · Cited by 16
Lee, C., Lee, S., & Hsu, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052042 · Cited by 14
“Yun et al. [28] conducted a study utilizing Ba/F3 cells with overexpression of EGFR Exon20ins and compared the antitumor activity of amivantamab (JNJ-61186372) to the first-and third-generation irreversible EGFR TKIs gefitinib and os-imertinib.”
Self-citationWang, D., Liu, Y., Chen, Y., Dai, C., Hu, W., Han, J., Li, Z., Yin, F., Zhang, Y., & Chen, S. (2025) · Advanced Science · doi:10.1002/advs.202510197 · Cited by 16
Zieliński, P., Stępień, M., Chowaniec, H., Kalyta, K., Czerniak, J., Borowczyk, M., Dwojak, E., Mroczek, M., Dworacki, G., Ślubowska, A., et al. (2025) · Cells · doi:10.3390/cells14080587 · Cited by 15
Exploring and bypassing resistance to targeted therapies in colorectal cancer
Favier, S., Xiong, W., Chalabi-Dchar, M., Chettab, K., Piercey, O., Wu, T., Fenouil, T., Albaret, M.-A., Jordheim, L. P., Diaz, J.-J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118741 · Cited by 12
Le, X., Robichaux, J. P., Nilsson, M. B., Vijayan, R. S. K., Ravichandran, A., Wu, J., Elamin, Y. Y., Hong, L., Pei, J., He, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61817-8 · Cited by 14
“Therefore, several EGFR ex20ins targeting agents have been developed, including amivantamab with FDA accelerated approval for treating EGFR ex20ins NSCLC. Amivantamab, an EGFR/MET bispeci fi c antibody, achieved an ORR of 40% and median progression-free survival (mPFS) of 8.3 months in a Phase I study (NCT02609776) 5 –…”
InfluentialTomasini, P., Wang, Y., Li, Y., Felip, E., Wu, L., Cui, J., Besse, B., Spira, A. I., Neal, J. W., Goto, K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02835 · Cited by 37
Self-citationRoles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer
Tang, R., Wang, H., & Tang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332814 · Cited by 15
Lim, S. M., Kang, S.-S., Kim, D. K., Lee, S., Synn, C., Baek, S., Yang, S. M., Han, Y. J., Kim, M. H., Han, H., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0107 · Cited by 12
“Amivantamab is a fully human bispecific antibody that binds to the EGFR and MET receptor to inhibit ligand binding, promote downregulation of cell surface receptors, and induce Fc-dependent immune activity (10–13).”
BackgroundSelf-citationAnalysis of EGFR binding hotspots for design of new EGFR inhibitory biologics
Tydings, C. W., Singh, B., Smith, A. W., Ledwitch, K. V., Brown, B. P., Lovly, C. M., Walker, A. S., & Meiler, J. (2024) · Protein Science · doi:10.1002/pro.5141 · Cited by 13
“…(N-methyl-N 0 - nitroso-guanidine osteosarcoma transforming gene) and EGFR bispecific antibody, amivantamab, binds to site 3 (Neijssen et al., 2021; Yun et al., 2020) and is FDA approved as a second-line treatment for locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations…”
BackgroundManagement of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Angelopoulos, P. A., Passaro, A., Attili, I., Aliaga, P. T., Corvaja, C., Spitaleri, G., Battaiotto, E., Signore, E. D., Curigliano, G., & de Marinis, F. (2025) · Genes · doi:10.3390/genes16070772 · Cited by 18
“The bispecific antibody amivantamab simultaneously binds to the EGFR and MET receptors, thus inhibiting ligand binding and promoting cell surface receptor downregulation [82].”
TAS2940 , a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations
Oguchi, K., Araki, H., Tsuji, S., Nakamura, M., Miura, A., Funabashi, K., Osada, A., Tanaka, S., Suzuki, T., Kobayashi, S. S., et al. (2022) · Cancer Science · doi:10.1111/cas.15617 · Cited by 12
Shah, V. S., McNatty, A., Simpson, L., Ofori, H., & Raheem, F. (2023) · Biomedicines · doi:10.3390/biomedicines11030950 · Cited by 13
“EGFR exon20ins mutation is a distinct subtype of EGFR oncogenic mutations that has been shown to be unresponsive to third-generation EGFR TKIs [8,9].”
BackgroundInfluentialPreclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
Groothuis, P. G., Jacobs, D. C. H., Hermens, I. A. T., Damming, D., Berentsen, K., Mattaar-Hepp, E., Stokman, M. E. M., van Boekel, T., Rouwette, M., van der Vleuten, M. A. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0596 · Cited by 12
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Favorito, V., Ricciotti, I., Giglio, A. D., Fabbri, L., Seminerio, R., Federico, A. D., Gariazzo, E., Costabile, S., & Metro, G. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2331139 · Cited by 15
“Furthermore, the low incidence of severe toxicities despite a lack of selectivity against wild-type EGFR may be owed to the bispecific nature of amivantamab, which increases efficacy through potential synergistic effects and selectivity through avidity effects [21,159].”
BackgroundInfluentialChimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
Xu, C., Ju, D., & Zhang, X. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac006 · Cited by 17
Cai, B., Li, X., Huang, X. L., Ma, T., Qu, B., Yu, W., Yang, W., Zhang, P., Chen, J., & Liu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738832 · Cited by 12
“Amivantamab inhibits EGFR/MET signaling through three mechanisms: internalization and degradation of EGFR/MET receptors, blocking ligand-dependent receptor activation, and antibody-dependent cell-mediated cytotoxicity (ADCC) (28).”
BackgroundNew Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer
Zhou, Y., Takahashi, J., & Sakurai, H. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00924 · Cited by 13
Oh, S. Y., Park, S., Lee, S.-Y., Lee, E. J., Kim, T. H., Choi, S., Park, S. Y., Kim, J. H., Lim, S. M., Lee, J. B., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101929 · Cited by 18
Self-citationZhang, Y., Li, Y., Han, Y., Li, M., Li, X., Fan, F., Liu, H., & Li, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175571 · Cited by 11
Li, Y. L., YU, L., ZHOU, S., Zhou, H., & Wu, Q. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.059311 · Cited by 10
“Additionally, dual or multitarget TKIs, such as poziotinib, which targets EGFR/ HER2, and JNJ-61186372, which targets EGFR/MET, are in development [71].”
Khan, S. R., & Breadner, D. A. (2025) · Current Oncology · doi:10.3390/curroncol32040206 · Cited by 11
“The study will investigate the adverse events, ORR, and maximum tolerated dose.”
Wu, Q., Li, Q., & Qin, Y. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108533 · Cited by 10
Pagliarini, R. A., Henderson, J. A., Milgram, B. C., Borrelli, D. R., Brooijmans, N., Hilbert, B. J., Huff, M. R., Ito, T., Kryukov, G. V., Ladd, B., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3833 · Cited by 11
“…large part dependent on nonautonomous immune-mediated effects, including antibody-dependent cellular cytotoxicity and monocyte/macrophage trogo-cytosis (67, 68), Ba/F3 proliferation assays do not appropriately measure amivantamab’s full mechanism of action in the absence of immune cell coculture.”
Köhler, J., & Janne, P. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01494 · Cited by 12
Sompallae, R. R., Dundar, B., Guseva, N. V., Bossler, A., & Ma, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1163485 · Cited by 10
“Targeted therapy for patients with this aberration showed sustained response (12, 13).”
BackgroundHaddish‐Berhane, N., Su, Y., Russu, A., Thayu, M., Knoblauch, R. E., Mehta, J., Xie, J., Gibbs, E., Sun, Y., & Zhou, H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3064 · Cited by 10
Self-citationOrganoids derived from metastatic cancers: Present and future
Zheng, X., Zhang, X., & Yu, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30457 · Cited by 11
Yao, H., Tong, X., & Wang, M. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006957 · Cited by 10
Alexander, M., Cheng, Y., Lee, S.-H., Passaro, A., Spira, A. I., Cho, B. C., Lim, S. M., Ohe, Y., Nagrial, A. M., Tan, J. L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115624 · Cited by 9
Self-citationAmivantamab: A New Hope in Targeting Non-small Cell Lung Cancer
Chawla, P. A., Billowria, K., & Gupta, G. D. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220523145609 · Cited by 10
Hintzen, G., Dulat, H. J., & Rajkovic, E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.892212 · Cited by 9
Pan, B., Liang, J., Shi, H., Rao, K., Guo, W., & Zhan, C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15127 · Cited by 10
Thomson, C., Bartoň, P., Braybrooke, E. L., Colclough, N., Dong, Z., Evans, L., Floc’h, N., Guerot, C. M., Hargreaves, D., Khurana, P., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00227 · Cited by 9
Tamiya, A., Osuga, M., Harada, D., Isa, S., Taniguchi, Y., Nakamura, K., Mizumori, Y., Shinohara, T., Yanai, H., Nakatomi, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107917 · Cited by 10
The MET Oncogene: An Update on Targeting Strategies
Gallo, S., Folco, C. B., & Crepaldi, T. (2024) · Pharmaceuticals · doi:10.3390/ph17111473 · Cited by 10
“Its effectiveness in tumors with Exon20 insertions (Exon20ins) has also been reported [132].”
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations
McCoull, W., Thomson, C., Braybrooke, E. L., Chan, C., Colclough, N., Gonzalez, M. A. C., Cosulich, S. C., Davies, N. L., Floc’h, N., Greenwood, R. D. R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02811 · Cited by 10
Mancini, M., Thomas, Q. D., Bourdel, S., Papon, L., Bousquet, E., Jalta, P., Monica, S. L., Travert, C., Alfieri, R. R., Quantin, X., et al. (2021) · Cancers · doi:10.3390/cancers13143441 · Cited by 9
“The rtTA, EGFR and MET transgenes were detected by PCR from DNA tails as described previously [18–20].”
BackgroundInfluentialYao, H., Tong, X., & Wang, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.002 · Cited by 9
Yue, P., Zhang, M., Feng, Y., Gao, Y., Sun, C., & Chen, P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368804 · Cited by 9
Chen, M. F., Lee, J. J.-K., Choudhury, N. J., Hui, A. B., Jeng, M. Y., Zheng, J., Aly, R. G. M., Sielski, N., Ahn, L. S. H., Pupo, A., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.10.012 · Cited by 16
Drug development and evidence for lung cancer targeted therapy in Eastern Asia
Liu, S. M., Jin, Z., Deng, J., Zhong, S.-M., Ahn, M., Horinouchi, H., Li, Y., & Wu, Y.-L. L. C. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101090 · Cited by 9
Al‐Huseini, I., Sirasanagandla, S. R., Babu, K. S., Sofin, R. G. S., & Das, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220117114306 · Cited by 9
Okuma, Y., Shimokawa, M., Hashimoto, K., Mizutani, H., Wakui, H., Murakami, S., Atagi, S., Minato, K., Seike, M., Ohe, Y., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-0892 · Cited by 8
All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations
Batra, U., Nathany, S., Mansi, S., Narayan, S., Jain, P., Dhanda, S., Jose, J. T., & Anurag, M. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04033-x · Cited by 12
“The emergence of newer drugs, such as poziotinib (Vyse 2019) and amivantanab (Yun et al. 2020), might be promising, particularly for inherently resistant exon 20 insertion mutations.”
BackgroundMan, X., Sun, X., Chen, C., Xiang, Y., Zhang, J., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1367204 · Cited by 9
Liu, H., Qin, J., & Qian, X. (2024) · Cancer Control · doi:10.1177/10732748241292782 · Cited by 11
“45,46 Capitalizing on the signi fi cant ef fi cacy demonstrated in second-line and subsequent treatment regimens, the PAPILLON study (NCT04538664), a randomized, open-label phase III clinical trial, evaluated amivantamab in combination with chemotherapy as a fi rst-line therapeutic option for patients…”
BackgroundCho, B. C., Hayashi, H., Lee, J.-S., Lee, S.-H., Danchaivijitr, P., Cheng, Y., Liu, B., Alip, A., Xiong, H., How, S. H., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108496 · Cited by 8
Self-citationWang, J., Liu, H., Ran, X., Tan, W., & Liu, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123502 · Cited by 8
Organoid-based precision cancer modeling: New frontier in lung cancer research
Terai, H., Yasuda, H., & Sato, T. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116595 · Cited by 10
Zhang, W., Zhang, X., Zhao, W., Guo, Z., Liu, X., Li, Y., Chen, Z., Xu, K., Liu, Y., Wang, H., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03438-3 · Cited by 10
Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7
Choi, D.-H., Jung, H. A., Park, S., Sun, J., Ahn, J. S., Ahn, M., & Lee, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-643 · Cited by 8
Self-citationTateyama, N., Suzuki, H., Ohishi, T., Asano, T., Tanaka, T., Mizuno, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112494 · Cited by 6
Anticancer α-, γ-, and δ-carboline derivatives: structures, mechanisms of action, and SARs
Cui, J., Gao, W., Liu, Z., Cao, S., & Long, S. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100221 · Cited by 7
Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations
Sabari, J. K., Heymach, J. V., & Sandy, B. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0200 · Cited by 8
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
Lim, S. M., Lee, J. B., Oya, Y., Nützinger, J., & Soo, R. A. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00273 · Cited by 6
Self-citationGuo, M. Z., Marrone, K. A., Spira, A. I., Freeman, K., & Scott, S. C. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.17.1.42 · Cited by 12
Immunotherapeutic and their immunological aspects: Current treatment strategies and agents
Jain, M., Mishra, A., Singh, M. K., Shyam, H., Kumar, S., Shankar, P., & Singh, S. (2022) · National Journal of Maxillofacial Surgery · doi:10.4103/njms.njms_62_22 · Cited by 7
“been shown to be effective anti‐EGFR therapies in clinical trials.[60,61]”
BackgroundLu, H.-L., Jie, G., & Wu, Y.-L. L. C. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2063836 · Cited by 8
“Amivantamab is a bispecific antibody targeting EGFR and MET, which can block EGFR/MET pathway synchronously [72].”
BackgroundSingh, D., & Sahoo, A. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928267931231120065335 · Cited by 7
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 8
“[253] For example, amivantamab, a bispecific antibody targeting both EGFR and MET receptors, inhibits ligand binding and promotes receptor down-regulation, [254] and exerts immunomodulatory effects via antibody-dependent cellular cytotoxicity (ADCC) and Fc-dependent phagocytosis.”
A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect
Bai, Y., Li, R., Zhang, X., Seng, D., Xu, Y., Zhang, S., & Yuan, S. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2704735 · Cited by 6
Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer
Wang, H., Wang, L., Gao, N., Li, H., Yang, F., Liu, Z., Li, H., & Li, X. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108641 · Cited by 9
Metadata
- Authors
- Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., Lim, S. M., Hong, M. H., Kim, H. R., Thayu, M., Curtin, J. C., Knoblauch, R. E., Lorenzi, M. V., Roshak, A., & Cho, B. C.
- Affiliations
- Yonsei University (KR)
- Jeuk (South Korea) (KR)
- 4Janssen Research and Development, Spring House, Pennsylvania.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1194-1209
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3024670790
- Cited by
- 297
- References
- 47
- Citations by year
- 2026: 32 · 2025: 60 · 2024: 45 · 2023: 52 · 2022: 49 · 2021: 47 · 2020: 11
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Ministry of Science, ICT and Future Planning (NRF-2016R1A2B3016282, 2018R1C1B6008916)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- amivantamab, EGFR-MET bispecific antibody, EGFR exon 20 insertion, non-small cell lung cancer, anticancer activity, EGFR tyrosine kinase inhibitors, immune checkpoint blockade, interferon-gamma, patient-derived organoids, xenograft models, cetuximab, poziotinib, Ba/F3 cells
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Carcinoma, Non-Small-Cell Lung, Exons, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Antibodies, Bispecific, Proto-Oncogene Proteins c-met, Cell Line, Tumor, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.